Pertussis Vaccine Market

Global Pertussis Vaccine Market Size

The size of the global pertussis vaccine market was worth USD 5.6 billion in 2024. The global market is anticipated to grow at a CAGR of 3.8% from 2025 to 2033 and be worth USD 7.83 billion by 2033 from USD 5.81 billion in 2025.

At a global level, the pertussis vaccine market substantially moves forward with tremendous opportunities over the past decade. The pertussis vaccine protects from whooping cough. It is generally recommended for children and pregnant ladies. This vaccine will be given to children starting at six months three times. For pregnant women, these vaccines are provided to protect the baby. The pertussis vaccine is a combination of tetanus and diphtheria vaccines. Around 85% of children will get prevented from whooping cough with this vaccine. It combines immunizations against tetanus, diphtheria, polio, and Haemophilus influenza type B. It is one of the most common vaccines given across the world. The pertussis vaccine has lower adverse effects, that are, it has fewer side effects, which can be negligible. In addition, recent studies stated that the pertussis vaccine effectively controls mutations in pathogens, which it cannot handle by another type of vaccine.

MARKET DRIVERS

The growing need for vaccination for children to protect them from various diseases is one of the major factors propelling the pertussis vaccine market growth.

According to the World Health Organization (WHO) data, 90% of DTP vaccine coverage was available in 126 countries in 2015.  DTP vaccines are given to safeguard children from infectious diseases such as diphtheria, tetanus, and pertussis. These diseases can be life-threatening. Hence, vaccination is inevitable. DTP vaccine is one of the most trusted vaccines to protect children from these diseases.

The growing birth population globally is fuelling the global pertussis vaccine market growth.

Pertussis is also famous as whooping cough and is an infectious respiratory disease, noticeable among children especially. Because of that, pertussis vaccines are given to children as part of their routine vaccination schedules worldwide. In addition, the growing birth population worldwide is anticipated to result in the pertussis vaccine market growth. For instance, according to the Centers for Disease Prevention and Control (CDC), an estimated 3.65 million births happened in the United States in 2021, which was a 1% increase from 2020. Furthermore, the increasing support and funding from the governments for immunization programs and growing awareness through advertisements and other forms are anticipated to fuel the growth rate of the pertussis vaccine market in the coming years. In addition, changes in the vaccine formulation to have fewer or no side effects create a chance for the pertussis vaccine market to grow.

MARKET RESTRAINTS

However, the lack of standardization is slightly restraining the market's growth. In addition, the rise in adverse events and lack of knowledge about the vaccine in rural areas hinders the pertussis vaccine market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Type Insights

The DTaP segment is forecasted to hold a major share of the global pertussis vaccine market during the forecast period based on product type. This segment accounted for 3/5th of the total share globally in 2019 and is estimated to maintain its dominance throughout the period. Rising demand for DTaP vaccines and the appearance of key players together with research and development labs. The extensive availability of advanced systems boosts the growth of the DTaP vaccine segment in the market.

The Tdap vaccine segment is projected to represent the highest CAGR during the forecast period.

By Vaccine Type Insights

Based on the vaccine type, the acellular vaccine segment is more popular than the whole-cell vaccine due to its low side effects and is expected to lead the market in the coming years

By Age Group Insights

The pediatric segment accounts for the largest share in the pertussis vaccine market based on the age group, accounting for 3/4th of the total share. It is retained to dominate throughout the forecast period with a CAGR of 4.9%. Increasing the pediatric population, acquiring pertussis vaccine, government initiatives, and favorable reimbursement policies lead to market growth. In addition, it is very protective and cost-effective for a pertussis-free environment. However, more than 117 million children from 37 countries are predicted to miss out on the program due to the eruption of COVID-19 in 2020. 

The adult segment is anticipated to witness the highest global CAGR of 5.5% in the market.

By End User Insights

Based on end-user, the vaccine centers segment had the highest share of the global pertussis vaccine market in 2022.

REGIONAL ANALYSIS

Geographically, North America led the pertussis vaccine market in 2022. The growing adoption of vaccines to protect children from various diseases is one of the major factors propelling the pertussis vaccine market in North America. As a result, North America is forecasted to play a key role in the global pertussis vaccine market. In addition, factors such as an increase in the aging population, favorable reimbursement policies, and growing usage of pertussis vaccines are likely to boost market growth in the North American region. The U.S. is anticipated to lead the North American region with the swelling in death rates from whooping cough and a surge in pertussis death rate driving the pertussis vaccine market. In 2014, 28,660 cases of pertussis were recorded in the US, according to CDC.

On the other hand, Europe accounted for a substantial share of the global market in the recent past owing to the growing birth population and increased government initiatives. As a result, Europe closely followed the North American region in 2021 and had the second-largest share of the worldwide market. Growing government initiatives for the welfare of pediatrics and adults, growing awareness through advertisements, and increasing usage of vaccines, particularly for children to maintain a healthy lifestyle, drive the pertussis vaccine market growth in Europe. The UK led the market in Europe, followed by Germany in the recent past.

The pertussis vaccine market in the Asia-Pacific is expected to have the fastest CAGR in the global market during the forecast period owing to rapid population growth, a rise in acquisition for vaccination, and a surge in common infectious diseases. 

The pertussis vaccine market in Latin America is expected to grow steadily during the forecast period. Brazil dominated the market, followed by Mexico in 2021, and is expected to generate growth opportunities for the pertussis vaccine market. In addition, an increase in the number of government and private healthcare insurance coverage and a rise in healthcare expenses are propelling the market growth in the region.

The Middle East & Africa is expected to have a minor share in the global pertussis vaccine market, with an increase in the pediatric population and a swelling in measurements taken by the pharmaceutical industries to develop the vaccine.

KEY MARKET PARTICIPANTS

Some key companies playing a leading role in the global pertussis vaccine market profiled in this report are Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp. and Astellas Pharma US, Inc.

RECENT MARKET HAPPENINGS

• In February 2020, Sanofi Pasteur developed the COVID-19 vaccine with the US government. In addition, the global business unit of French drugmaker Sanofi has joined forces with a US government department to develop a novel COVID-19 coronavirus vaccine. 
• In February 2020, Sanofi partnered with the US for a virus vaccine. In addition, the major pharma Sanofi said it would leverage its development work for a SARS vaccine to develop a potential vaccine for COVID-19. 
• In February 2020, HHS engaged Sanofi's recombinant technology for the 2019 novel coronavirus vaccine. In addition, HHS will provide expertise and reallocate funds to Sanofi to develop a vaccine against the 2019 novel coronavirus vaccine.
• In November 2019, Sanofi’s high-dose quadrivalent flu vaccine was approved for older people.
• In June 2019, Sanofi Pasteur and Chhota Bheem joined hands to drive awareness and action on the flu. In addition, Sanofi and Mirum have planned a digital campaign to drive awareness and work around the perils of the flu.  
• In February 2020, A Chinese biotech partnered with GSK to boost its development of a coronavirus vaccine. GSK partnered with China biotech to develop a product that can stop the infection from the coronavirus. 

MARKET SEGMENTATION

This research report on the global pertussis vaccine market has been segmented and sub-segmented into the following categories.

By Product Type

• DTaP Vaccine
  • Daptacel
  • Infanrix
  • Kinrix
  • Pediarix
  • Pentacel
  • Quaracel
• Tdap Vaccine
  • Boostrix
  • Adacel

By Vaccine Type

• Whole-Cell Vaccine
• Acellular Vaccine

By Age Group

• Adult
• Pediatric

By End User

• Hospitals
• Clinics
• Vaccine Centers

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa